Novartis receives European approval for Cosentyx
European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
Aim is to predict novel catalysts using machine learning (ML) and artificial intelligence (AI) techniques
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
The project is part of a three-year-long partnership between Honeywell and Americares to strengthen the health infrastructure in rural Maharashtra, Uttarakhand and Haryana
The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock
HMD had supplied 921.7 million syringes to the Government of India to facilitate over 2.2 billion Vaccination in India till date
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
Subscribe To Our Newsletter & Stay Updated